GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Coeptis Therapeutics
Coeptis, an early-stage oncology biotech, is a highly speculative bet on science. Its price is driven not by financial performance, but by news from preclinical and early clinical trials that could hint at a future breakthrough.
Share prices of companies in the market segment - Cancer blood
Coeptis Therapeutics is a biopharmaceutical company focused on developing and licensing innovative cell therapies, particularly for the treatment of blood cancers. We've classified it in the "Cancer Blood" segment. The chart below shows the overall dynamics of this cutting-edge, yet high-risk, biotech sector.
Broad Market Index - GURU.Markets
Coeptis Therapeutics is a biopharmaceutical company developing cell therapies and diagnostic tools for cancer treatment. Its focus on oncology makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Coeptis compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
COEP - Daily change in the company's share price Coeptis Therapeutics
Coeptis Therapeutics' daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about its cell therapy clinical trials, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Cancer blood
Coeptis Therapeutics Holdings, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with COEP's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Coeptis Therapeutics is a biotech company developing cell therapy for blood cancer. Its shares are a bet on a scientific breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovative market sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Coeptis Therapeutics
For Coeptis Therapeutics, year-over-year performance is a story about its cell therapy pipeline. Its 12-month market cap depends entirely on progress in the preclinical and clinical programs it develops through licensing and partnerships. Its valuation is a bet on one of these assets taking off.
Annual dynamics of market capitalization of the market segment - Cancer blood
As an early-stage biotech, Coeptis is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials. Its stock price will reflect investors' speculative belief in the potential of its unique developments in oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Coeptis Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Coeptis Therapeutics
Coeptis Therapeutics is a biotech company focused on cell therapy. Its monthly performance is typical for the sector: it depends entirely on progress in its scientific developments and clinical programs. Partnerships and licensing announcements are key.
Monthly dynamics of market capitalization of the market segment - Cancer blood
Developing cell therapies for blood cancer is one of the most advanced and risky segments of biotech. Its market capitalization dynamics, visible on the chart, reflect investors' faith in scientific breakthroughs. Companies like Coeptis Therapeutics are conducting their early research in this environment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Coeptis Therapeutics is a clinical-stage oncology company. Its shares exist in a world of their own: their price rises and falls based on trial data, paying little attention to overall market trends. This chart illustrates this disconnect.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Coeptis Therapeutics
For Coeptis Therapeutics, an early-stage oncology company, weekly performance is highly volatile and speculative. Any news related to its cell therapy technologies, whether patented or preclinical, could cause sharp price movements.
Weekly dynamics of market capitalization of the market segment - Cancer blood
Coeptis Therapeutics and the entire cell therapy sector are moving against a backdrop of scientific breakthroughs and investor anticipation. Regulatory news is creating extreme volatility for everyone. The chart will show whether the company is leading the hype.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Coeptis Therapeutics and the entire cell therapy sector are moving against a backdrop of scientific breakthroughs and investor anticipation. Regulatory news is creating extreme volatility for everyone. The chart will show whether the company is leading the hype.
Market capitalization of the company, segment and market as a whole
COEP - Market capitalization of the company Coeptis Therapeutics
Coeptis Therapeutics' market cap is the financial valuation of an early-stage biotech company focused on cell therapy for cancer. The chart reflects investor expectations for its portfolio of licensed technologies. Its speculative dynamics tell the story of how the market evaluates scientific potential in the absence of clinical data and revenue.
COEP - Share of the company's market capitalization Coeptis Therapeutics within the market segment - Cancer blood
Coeptis Therapeutics is a biopharmaceutical company focused on developing cell therapies for the treatment of cancer, particularly blood cancers. Its market share reflects the potential of its development pipeline and licensing agreements. The chart below shows how the market views its prospects in this competitive field.
Market capitalization of the market segment - Cancer blood
Coeptis Therapeutics is developing cell therapies for cancer treatment. The chart below shows the sector's overall market capitalization. Its dynamics reflect the enormous hope that we will be able to use our own cells to fight cancer. Coeptis, like many others, is part of this scientific quest.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cell therapy, as seen on the chart, is seeking new targets. Coeptis Therapeutics develops technologies to improve existing cell therapies, such as CAR-T. Its capitalization is a risky bet on its platforms, which could make cancer treatment more effective and safe.
Book value capitalization of the company, segment and market as a whole
COEP - Book value capitalization of the company Coeptis Therapeutics
Coeptis's book value is capital for cell therapy development. Currently in the R&D stage, the company uses its financial assets to advance technologies aimed at improving CAR-T therapy and creating new treatments for blood cancer.
COEP - Share of the company's book capitalization Coeptis Therapeutics within the market segment - Cancer blood
Coeptis Therapeutics, a cell therapy company, is at an early stage. Its share of the sector's assets is minimal, consisting of R&D assets. Its value lies in its technologies and partnerships, rather than in the ownership of a large manufacturing base at this stage.
Market segment balance sheet capitalization - Cancer blood
Coeptis Therapeutics is a cell therapy company in the R&D stage, which accounts for its low capital intensity. Its value lies in its technology and research data, not its manufacturing capacity. Compared to the broader biotech sector, its "light" balance sheet is typical of innovative companies focused on science.
Book value of all companies included in the broad market index - GURU.Markets
Coeptis' assets are not factories, but licenses for promising cell therapy technologies to fight cancer. The company's balance sheet reflects the value of this intellectual property and the potential of its developments. The chart shows how much capital has been invested in building a portfolio of innovative oncology assets.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Coeptis Therapeutics
Coeptis Therapeutics is a biotech company focused on cell therapy. Its market value is a speculative valuation of its scientific developments and partnerships. Investors are betting on its potential to treat cancer, creating a huge gap with its minimum book value.
Market to book capitalization ratio in a market segment - Cancer blood
Coeptis Therapeutics is a biotech company focused on cell therapy for cancer. Its market valuation is based entirely on the potential of its scientific developments. This chart illustrates a classic pattern for this sector: valuation driven by hope, unrelated to tangible assets.
Market to book capitalization ratio for the market as a whole
Coeptis Therapeutics is an oncology company developing cell therapy. Its value is determined by the potential of this innovative technology. This chart illustrates the extent to which biotech market valuations are based on future scientific breakthroughs rather than current tangible assets, which contrasts sharply with the market average.
Debts of the company, segment and market as a whole
COEP - Company debts Coeptis Therapeutics
Coeptis Therapeutics is a biotechnology company focused on cancer cell therapy. Its strategy often involves licensing and developing technologies discovered by others. Debt financing can be used to acquire such licenses and fund clinical trials for these promising assets.
Market segment debts - Cancer blood
Coeptis Therapeutics is a development-stage biotech company specializing in cancer cell therapy. Funding for such companies is vital and typically comes from equity investors. This chart shows whether the company adheres to this standard model or seeks alternative sources of capital for its research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Coeptis Therapeutics
Coeptis Therapeutics, focused on treating blood cancer, is in clinical development, requiring enormous capital expenditures. This chart shows its debt load. In biotech, this is a risky proposition: borrowed funds are wasted in research, and if the drug isn't approved, the company will be left with nothing but liabilities to its creditors.
Market segment debt to market segment book capitalization - Cancer blood
Coeptis Therapeutics focuses on developing cell therapies for the treatment of oncological diseases, particularly blood cancers. This chart compares the debt raised for this cutting-edge but risky research to the overall market capitalization of the entire sector. It reflects the enormous financial demands associated with developing next-generation therapies.
Debt to book value of all companies in the market
Coeptis Therapeutics is focused on developing cell therapies for cancer treatment. This line of biotechnology requires colossal long-term investments. The chart allows investors to assess how the company finances its expensive clinical trials. Its debt load, compared to the market, shows the extent of its reliance on external capital to achieve success.
P/E of the company, segment and market as a whole
P/E - Coeptis Therapeutics
For Coeptis Therapeutics, a company working in cell therapy for blood cancer, this chart is a pure bet on science. Since the company has no commercial products, its value is based on the potential of its developments. Share price movements reflect investor reactions to lab news and early clinical trial data.
P/E of the market segment - Cancer blood
This chart reflects the average valuation for the speculative cell therapy sector—a benchmark for Coeptis. The entire sector is valued based on expectations for future breakthroughs. For investors, this benchmark reflects the overall level of faith in the technology. This provides a useful framework for assessing expectations for Coeptis's developments.
P/E of the market as a whole
Coeptis Therapeutics is a biotech company focused on developing cell therapies for cancer treatment. It is developing technologies that could make CAR-T therapy more accessible and universal. This chart shows the overall interest in biotech, providing insight into how the market views Coeptis' scientific approach and its potential to improve one of the most advanced cancer treatments.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Coeptis Therapeutics
Coeptis Therapeutics is a biopharmaceutical company focused on cell therapy. Its future profitability depends on the success of its research programs and partnerships. For an early-stage company, this timeline is speculative and reflects analysts' confidence in the potential of its technologies to develop new cancer treatments.
%20P%2FE%20Coeptis%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Coeptis-Therapeutics&v=1772682613831 "Chart of the company's future (projected) P/E Coeptis Therapeutics")
Future (projected) P/E of the market segment - Cancer blood
Coeptis Therapeutics is a biopharmaceutical company focused on developing cell therapies for the treatment of oncology. This chart shows how its profitability expectations compare to the biotech sector. It reflects the market's perception of its technology portfolio, including platforms for improving CAR-T therapy, and its strategy for developing these assets.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772682613857 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
Coeptis Therapeutics is a biotech company focused on cell therapy for cancer treatment. This chart shows the company's overall risk appetite. Coeptis's success depends on progress in its scientific programs and clinical trials. A positive market environment is important for raising capital, but is not a determinant of long-term success.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772682613946 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Coeptis Therapeutics
Coeptis Therapeutics is a biopharmaceutical company focused on developing cell therapies for the treatment of oncological diseases, particularly blood cancers. This chart shows the company's financial progress through preclinical and early clinical trials. Current results reflect investments in the development of innovative treatments.
Profit of companies in the market segment - Cancer blood
Coeptis Therapeutics is a biopharmaceutical company focused on developing cell therapies for the treatment of oncological diseases, particularly blood cancers. The company develops innovative platforms. This chart illustrates the total revenue in the oncology sector, highlighting the commercial potential and risks associated with developing advanced cancer treatments.
Overall market profit
Coeptis Therapeutics is a biotech company focused on cancer cell therapy. Its prospects are driven by scientific developments and clinical trial results. Economic cycles don't affect treatment demand, but the overall market conditions and investor risk appetite, reflected in this chart, are important for raising capital.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Coeptis Therapeutics
Coeptis Therapeutics is an early-stage biotechnology company working in the field of cancer cell therapy. Its future depends entirely on the success of preclinical and clinical trials. Its profit projections are highly speculative, reflecting only the remote likelihood of commercial success.
%20profit%20of%20the%20company%20Coeptis%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Coeptis-Therapeutics&v=1772682614103 "Graph of future (projected) profit of the company Coeptis Therapeutics")
Future (predicted) profit of companies in the market segment - Cancer blood
Coeptis Therapeutics is focused on developing cell therapies for the treatment of oncology. This chart shows the outlook for the biotech sector, where the risks are high but the potential rewards are enormous. Coeptis's future profitability depends entirely on its research and its ability to bring innovative treatments to patients through all stages of clinical trials.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772682614115 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
Coeptis Therapeutics is developing cell therapies for the treatment of oncology. The company's success, currently in the research stage, is entirely dependent on raising capital. This graph, which displays projected total returns, serves as a barometer of the investment climate and demonstrates how willing investors are to fund risky but potentially breakthrough projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772682614119 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Coeptis Therapeutics
Coeptis Therapeutics is a biopharmaceutical company focused on developing cell therapies for the treatment of cancer. This chart shows a valuation based solely on future potential. It reflects investor expectations that its technologies, such as SNAP-CAR, will be a breakthrough in the fight against cancer.
P/S market segment - Cancer blood
Coeptis Therapeutics is a biopharmaceutical company developing cell therapies for cancer, including technologies to improve the efficacy and safety of CAR-T therapy. This chart reflects the average biotech valuation, helping to understand how investors view the potential of Coeptis' technologies to improve existing cancer treatments.
P/S of the market as a whole
Coeptis Therapeutics is a biotech company working in cell therapy, specifically on technologies to improve the effectiveness of CAR-T cancer therapy. This graph of average market revenue valuations contrasts sharply with Coeptis's value, showing that its valuation is based on its potential to improve existing cancer treatments.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Coeptis Therapeutics
Coeptis Therapeutics is focused on developing cell therapies for the treatment of oncology. This chart reflects investors' confidence in the future success of its innovative approaches. The valuation is based on potential revenues from its therapeutic products, which are currently in early development and clinical trials.
%20P%2FS%20Coeptis%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Coeptis-Therapeutics&v=1772682614403 "The graph of the company's future (projected) P/S Coeptis Therapeutics")
Future (projected) P/S of the market segment - Cancer blood
Coeptis Therapeutics focuses on developing cell therapies for the treatment of oncology. This chart compares the company's future revenue expectations with its industry. For a clinical-stage company, it reflects investor confidence in its scientific developments and the potential of future drugs.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772682614450 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
Coeptis Therapeutics is a biopharmaceutical company focused on developing cell therapies for the treatment of oncology. This schedule reflects confidence in future growth, and Coeptis is working at the forefront of science. The success of its innovative approaches to CAR-T therapy may offer new hope for patients with blood cancer.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772682614462 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Coeptis Therapeutics
Coeptis Therapeutics is a biopharmaceutical company focused on developing cell therapies for the treatment of cancer. Being in the research stage, the company has no commercial products, and its revenue, if reflected in this chart, likely comes from licensing agreements or partnerships rather than sales.
Sales of companies in the market segment - Cancer blood
Coeptis Therapeutics is a biopharmaceutical company developing cell therapies for cancer treatment. They focus on technologies that can improve the efficacy and safety of existing approaches. This graph reflects the dynamics of the oncology sector, where continuous innovation, like that of Coeptis, drives science forward.
Overall market sales
Coeptis Therapeutics is focused on developing cell therapies for the treatment of cancer. Its operations rely on capital inflows into the biotech sector. Periods of revenue growth, as reflected in this chart, increase investor risk appetite. This makes it easier for companies like Coeptis to raise funding for expensive research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Coeptis Therapeutics
Coeptis Therapeutics is a biopharmaceutical company developing cell therapies for cancer treatment, particularly those based on CAR-T technology. The future revenue forecast in this chart is entirely dependent on analyst expectations for the success of its clinical programs and the potential market launch of innovative oncology drugs.
%20sales%20of%20the%20company%20Coeptis%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Coeptis-Therapeutics&v=1772682614640 "Schedule of future (projected) sales of the company Coeptis Therapeutics")
Future (projected) sales of companies in the market segment - Cancer blood
Coeptis Therapeutics is a biopharmaceutical company focused on developing cell therapies for the treatment of cancer. This chart shows forecasts for the oncohematology sector. It helps understand how the cutting-edge technologies being developed by Coeptis fit into the overall picture of the rapidly evolving cell therapy market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772682614764 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
Coeptis Therapeutics, which focuses on cell therapy, sees this chart as an indicator of the overall health of the biotech sector. The positive economic outlook reflected here is fueling increased R&D funding and M&A activity, creating a favorable environment for the development of small, innovative companies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772682614815 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Coeptis Therapeutics
Coeptis Therapeutics is a biotechnology company focused on developing cell therapies for the treatment of cancer. Being in the research stage, the company does not generate sales revenue. This chart reflects its investment phase, showing how capital is used to fund research and development to create breakthrough cancer treatments.
Market segment marginality - Cancer blood
Coeptis Therapeutics focuses on developing cell therapies for the treatment of oncological diseases, particularly blood cancers. For such a biotech startup, operational efficiency is critical to survival and successfully completing expensive research stages. The chart shows how the company manages its resources compared to competitors in this innovative field.
Market marginality as a whole
Coeptis Therapeutics is a biotech company focused on cell therapy. This chart shows current market profitability, and Coeptis is investing in future technologies that could offer new ways to fight cancer. Their financial history is a journey of research and development in anticipation of clinical success.
Employees in the company, segment and market as a whole
Number of employees in the company Coeptis Therapeutics
Coeptis Therapeutics is a biotech company focused on cell therapy for cancer. This graph illustrates how compact a team can be in the early stages of development. A small team of scientists and managers is focused on bringing their innovative technologies to the clinic.
Share of the company's employees Coeptis Therapeutics within the market segment - Cancer blood
Coeptis Therapeutics focuses on developing cell therapies for oncology. In this knowledge-intensive field, scientists and clinicians are its most valuable resource. The data presented demonstrates the proportion of all hematological oncology researchers that Coeptis attracts, demonstrating its scientific potential and focus on breakthrough treatments.
Number of employees in the market segment - Cancer blood
Coeptis Therapeutics is a biopharmaceutical company focused on developing cell therapies for the treatment of cancer. Its staff consists of scientists and clinical development specialists. This chart shows the company's R&D activity. Team growth is an indicator of progress in development and preparation for clinical trials.
Number of employees in the market as a whole
Coeptis Therapeutics specializes in developing cell therapies for cancer treatment. In the world of biotechnology, personnel dynamics follow their own laws. Successful preclinical research results can lead to a sharp expansion of the research staff, regardless of the overall economic situation, as reflected in this graph.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Coeptis Therapeutics (COEP)
Coeptis Therapeutics is another R&D biotech company. Its market capitalization is a bet on the future success of its drugs. This chart clearly demonstrates that market value is determined not by the number of employees, but by the potential of their discoveries. A high market capitalization is the norm for an innovative company.
%20of%20the%20company%20Coeptis%20Therapeutics%20(COEP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Coeptis-Therapeutics-COEP&v=1772682615542 "Chart of market capitalization per employee (in thousands of dollars) of the company Coeptis Therapeutics (COEP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
Coeptis Therapeutics focuses on developing cell therapies for the treatment of oncological diseases, particularly blood cancers. In this cutting-edge biotech field, market valuation reflects investors' faith in science. This chart shows how much the market values each scientist and employee working to save lives, compared to competitors.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772682615613 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
Coeptis Therapeutics is a biotech company focused on cell therapy and oncology. Being in the early stages, its value is based on the potential of its technology. This chart illustrates how investors value the intellectual property and scientific team whose work could lead to the creation of a new generation of cancer drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772682615644 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Coeptis Therapeutics (COEP)
Coeptis Therapeutics is a biotech company focused on developing cell therapy (CAR-T) for the treatment of blood cancers. It's a pure R&D business. This graph will be negative, reflecting the amount of research investment per scientist. This is a bet that their scientific platform will lead to a breakthrough therapy.
%20Chart%20Coeptis%20Therapeutics%20(COEP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Coeptis-Therapeutics-COEP&v=1772682615653 "Company Profit Per Employee (in thousands of dollars) Chart Coeptis Therapeutics (COEP)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
Coeptis Therapeutics (COEP) is a biopharmaceutical company specializing in the development of cell therapies for the treatment of oncological diseases, including blood cancers. Currently in the R&D stage, the company is focused on advancing its technologies. This chart does not show operating profit, but rather the efficiency with which the research team uses capital to advance its research.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772682615745 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
Coeptis Therapeutics is a biotech company focused on cell therapy for blood cancer. This is an early-stage R&D company, acquiring and developing technologies. This graph would show negative profit per employee, as all resources go toward funding research and the work of scientists. This is the price the company pays for developing a potentially breakthrough treatment.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772682616019 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Coeptis Therapeutics (COEP)
Coeptis Therapeutics is a biotech company focused on developing cell therapies for cancer treatment. During the research and development phase, this graph is an indicator of future potential. Any revenue per employee is likely to come from strategic alliances rather than commercial product sales.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Coeptis-Therapeutics-COEP&v=1772682616038 "Sales chart per company employee Coeptis Therapeutics (COEP)")
Sales per employee in the market segment - Cancer blood
Coeptis Therapeutics is a biotech company specializing in cell therapies for cancer treatment, including CAR-T technologies. This is a highly competitive field. This chart shows the average revenue per employee in the sector. It serves as a benchmark, demonstrating the level of productivity required to bring these complex and expensive treatments to market.
Sales per employee for the market as a whole
Coeptis Therapeutics (COEP) is a biotech company focused on developing cell therapy (CAR-T) for cancer treatment. It is an early-stage R&D company and is staffed by scientists. This graph shows the current (zero) commercial return per employee, as all resources are directed toward research and development.
Short shares by company, segment and market as a whole
Shares shorted by company Coeptis Therapeutics (COEP)
Coeptis Therapeutics is a biopharmaceutical company focused on developing cell therapies (CAR-T) for cancer treatment. This is a highly competitive field. The chart shows the number of investors betting that Coeptis' technology (for example, for CD38) will fail to stand out from the giants or will fail clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Coeptis-Therapeutics-COEP&v=1772682616408 "Short Shares Chart for the Company Coeptis Therapeutics (COEP)")
Shares shorted by market segment - Cancer blood
Coeptis Therapeutics works in cell therapy for blood cancer. This indicator measures bearish sentiment in the sector. It rises when investors generally doubt the commercial viability or safety of new cell therapies, anticipating industry-wide challenges beyond those already approved.
Shares shorted by the overall market
Coeptis Therapeutics is an early-stage biotech focused on cell therapy for blood cancer. This chart illustrates the overall market pessimism. When fear dominates, investors don't buy "science projects." They see a company that's just spending money and fear that funding will dry up before a product is developed.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Coeptis Therapeutics (COEP)
This chart for Coeptis Therapeutics reflects the extreme volatility in the cell therapy sector. The company focuses on blood cancer treatments, a sector with binary outcomes. Positive preclinical data or partnership news can trigger explosive "overheating" (above 70). Meanwhile, massive research costs and a long path to approval often keep the oscillator in "oversold" territory (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Coeptis-Therapeutics-COEP&v=1772682616583 "RSI 14 indicator chart for the company's stock Coeptis Therapeutics (COEP)")
RSI 14 Market Segment - Cancer blood
Coeptis (COEP) is a biotech company focused on blood cancer (CAR-T) therapy. The blood cancer (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether COEP's growth is due to its R&D or whether the entire biotech sector is simply overheated by expectations.
RSI 14 for the overall market
Coeptis (COEP) is a biotech R&D company. Like everyone in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast COEP (Coeptis Therapeutics)
Coeptis (COEP) is a clinical-stage biotech company developing cell therapies (including CAR-T) for the treatment of blood cancers. This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of the company's pipeline and the potential of its technologies.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-COEP-Coeptis-Therapeutics&v=1772682616732 "A chart showing analyst consensus forecasts for the expected stock price. COEP (Coeptis Therapeutics)")
The difference between the consensus estimate and the actual stock price COEP (Coeptis Therapeutics)
Coeptis Therapeutics (COEP) is a clinical-stage biotech developing cell therapy for blood cancer. This chart is a classic biotech barometer. It measures the vast gap between the current speculative price and analyst consensus price target. This gap reflects the enormous potential experts believe for the success of their R&D.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-COEP-Coeptis-Therapeutics&v=1772682616775 "A chart showing the difference between the consensus forecast and the actual stock price. COEP (Coeptis Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
Coeptis Therapeutics is a biotech company developing cell therapies (CAR-T) for the treatment of blood cancers. This chart shows analysts' overall expectations for the entire blood cancer sector. It reflects whether experts believe in a breakthrough in off-the-shelf cell therapies or consider the sector overheated.
Analysts' consensus forecast for the overall market share price
Coeptis is a clinical-stage biotech company specializing in cancer cell therapy. It's an R&D company that's burning cash. This chart, reflecting the market's overall risk appetite, is vital. When optimism is high, investors fund speculative science. When pessimism ("risk-off") takes over, funding for biotechs like COEP dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Coeptis Therapeutics
Coeptis Therapeutics is a biotech company working in the field of cell therapy. They focus on developing innovative platforms (including universal NK cells) for the treatment of blood cancers and solid tumors. This chart is a pure indicator of faith in their science. It doesn't reflect revenue, but rather a speculative market assessment of their R&D platform and clinical trial data.
AKIMA Market Segment Index - Cancer blood
Coeptis Therapeutics (COEP) is a biopharmaceutical company focused on developing cell therapies for cancer, specifically technologies to improve CAR-T therapy for hematologic malignancies. The chart shows the segment average. It helps investors assess how the risks and potential of Coeptis' developments compare to the average in the blood cancer sector.
The AKIM Index for the overall market
Coeptis Therapeutics is a biopharmaceutical company developing cell therapies (NK cells) and conjugates for cancer treatment. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story fits into the context of overall economic trends and partnerships.
